.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX52_Venetoclax.Venetoclax .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX52_Venetoclax.Venetoclax| name: | Venetoclax |
| ATC code: | L01XX52 | route: | oral |
| n-compartments | 2 |
Venetoclax is a selective inhibitor of B-cell lymphoma-2 (BCL-2) protein, used primarily for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It promotes apoptosis of cancer cells by inhibiting BCL-2, a protein that helps cancer cells survive. Venetoclax is an approved drug for hematological malignancies.
Pharmacokinetic parameters are based on adults with hematologic malignancies receiving single or multiple oral doses. The values mainly reflect patients with normal hepatic and renal function.
DiNardo, CD, et al., & Pollyea, DA (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet. Oncology 19(2) 216–228. DOI:10.1016/S1470-2045(18)30010-X PUBMED:https://pubmed.ncbi.nlm.nih.gov/29339097
Jones, AK, et al., & Salem, AH (2016). Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. The AAPS journal 18(5) 1192–1202. DOI:10.1208/s12248-016-9927-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27233802
King, AC, et al., & Tang, LA (2017). Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. The Annals of pharmacotherapy 51(5) 410–416. DOI:10.1177/1060028016685803 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28056525